Advance Search
XU Huachu, LI Feng, YANG Hongguang. Value of Clinical Pulmonary Infection Score in guiding treatment of tigecycline combined with cefoperazone sodium and sulbactam sodium for severe pneumonia patients[J]. Journal of Clinical Medicine in Practice, 2020, 24(19): 48-51. DOI: 10.7619/jcmp.202019014
Citation: XU Huachu, LI Feng, YANG Hongguang. Value of Clinical Pulmonary Infection Score in guiding treatment of tigecycline combined with cefoperazone sodium and sulbactam sodium for severe pneumonia patients[J]. Journal of Clinical Medicine in Practice, 2020, 24(19): 48-51. DOI: 10.7619/jcmp.202019014
shu

Value of Clinical Pulmonary Infection Score in guiding treatment of tigecycline combined with cefoperazone sodium and sulbactam sodium for severe pneumonia patients

  • Department of Critical Medicine, The First People's Hospital of Jiujiang City in Jiangxi Province, Jiujiang, Jiangxi, 332000

More Information
  • Received Date: July 26, 2020
    Graphical Abstract
    • Abstract
  • Objective To investigate the value of Clinical Pulmonary Infection Score(CPIS)in guiding the treatment of tigecycline combined with cefoperazone sodium and sulbactam sodium for severe pneumonia patients. Methods Totally 60 patients with severe pneumonia were selected and randomly divided into two groups, with 30 cases in each group. Control group was treated with antibiotics according to the experience, and observation group was treated with antibiotics under the guidance of CPIS. The drug regimen in both groups was tigecycline combined with cefoperazone sodium and sulbactam sodium. The symptom disappearance rate, application time of antibiotics, levels of inflammatory indexes［C reactive protein(CRP), procalcitonin(PCT), white blood cell count(WBC)］ and adverse reactions were compared between the two groups. Results After 2 weeks of treatment, the fever symptoms disappeared in both groups, and there were no significant differences in the disappearance rate of pulmonary rales and expectoration between the two groups(P>0.05). The application time of antibiotics in the observation group was(7.38±2.66)days, which was significantly shorter than(9.82±2.89)days in the control group(t=3.403, P=0.001). The levels of CRP, PCT and WBC in both groups after treatment were significantly lower than those before treatment(P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05). Conclusion Under the guidance of CPIS, tigecycline combined with cefoperazone sodium and sulbactam sodium is safe and effective in the treatment of severe - pneumonia patients, which can shorten the medication time and relieve the symptoms of patients.
    • FullText(HTML)
    • References (20)
  • 周欣, 姚高琼, 张成志, 等. 重庆市抗菌药物使用调查及干预前后对比分析研究[J]. 重庆医学, 2017, 46(11): 1508-1510.
    黄丽君, 郑丽贞. 抗菌药物联合用药现状调查与研究[J]. 中国生化药物杂志, 2017, 37(7): 403-405.
    刘华锋, 燕丽, 王磊, 等. 替加环素结合头孢哌酮钠舒巴坦钠治疗多药耐药鲍氏不动杆菌肺部感染患者的临床疗效[J]. 中华医院感染学杂志, 2017, 27(15): 3401-3403

    , 3410.
    LI T, SHENG M Y, GU T Z, et al. In vitro assessment of cefoperazone-sulbactam based combination therapy for multidrug-resistant Acinetobacter baumannii isolates in China[J]. Journal of Thoracic Disease, 2018, 10(3): 1370-1376.
    CHEN C Q, YAN M L, HU C B, et al. Diagnostic efficacy of serum procalcitonin, C-reactive protein concentration and clinical pulmonary infection score in Ventilator-Associated Pneumonia[J]. Medecine Sciences: M/S, 2018, 34(Focus issue F1): 26-32.
    石宏哲, 秦铮, 池卫华, 等. 重症肺炎MSCT图像征象、临床肺部感染评分与病情严重程度的相关性研究[J]. 中国CT和MRI杂志, 2019, 17(7): 79-81.
    中国医师协会急诊医师分会. 中国急诊重症肺炎临床实践专家共识[J]. 中国急救医学, 2016, 36(2): 97-107.
    WONGSURAKIAT P, TULATAMAKIT S. Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of nonfermentative gram-negative bacilli infection[J]. Ther Adv Respir Dis, 2018, 12: 1753466618760134.
    PFALLER M A, FLAMM R K, DUNCAN L R, et al. Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18, 386 Gram-negative organisms from Europe and the Asia-Pacific region(2013-2014)[J]. Diagnostic Microbiology and Infectious Disease, 2017, 88(2): 177-183.
    CHEN H, LIU Q, CHEN Z, et al. Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: a systematic review and meta-analysis[J]. J Infect Chemother, 2017, 23(5): 278-285.
    秦又发, 吴雷, 朱永坤, 等. 替加环素联合头孢哌酮-舒巴坦治疗广泛耐药鲍曼不动杆菌医院获得性肺炎临床疗效观察[J]. 中国感染与化疗杂志, 2015, 15(5): 430-433.
    GIAMMANCO A, CALÀ C, FASCIANA T, et al. Global assessment of the activity of tigecycline against multidrug-resistant gram-negative pathogens between 2004 and 2014 as part of the tigecycline evaluation and surveillance trial[J]. mSphere, 2017, 2(1): e00310-e00316.
    CHEN Z, SHI X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens[J]. Medicine(Baltimore), 2018, 97(38): e12467.
    聂晓莉, 闫春良, 赵秋红, 等. 医院内获得性肺炎抗菌药物的疗效和安全性比较[J]. 中国医院药学杂志, 2015, 35(13): 1225-1227.
    HARADA K, SEKIYA N, KONISHI T, et al. Predictive implications of albumin and C-reactive protein for progression to pneumonia and poor prognosis in Stenotrophomonas maltophilia bacteremia following allogeneic hematopoietic stem cell transplantation[J]. BMC Infectious Diseases, 2017, 17(1): 638-647.
    GARDNER J G, BHAMIDIPATI D R, RUEDA A M, et al. White blood cell counts, alcoholism, and cirrhosis in pneumococcal pneumonia[J]. Open Forum Infectious Diseases, 2017, 4(2): ofx034.
    ITO A, ISHIDA T, TOKUMASU H, et al. Impact of procalcitonin-guided therapy for hospitalized community-acquired pneumonia on reducing antibiotic consumption and costs in Japan[J]. Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy, 2017, 23(3): 142-147.
    PANDURANGAN A P, ASCHER D B, THOMAS S E, et al. Genomes, structural biology and drug discovery: combating the impacts of mutations in genetic disease and antibiotic resistance[J]. Biochemical Society Transactions, 2017, 45(2): 303-311.
    马莹, 李旺, 陈瑶, 等. 某院鲍氏不动杆菌耐药性与抗菌药物使用强度相关性分析[J]. 中华医院感染学杂志, 2020, 30(5): 648-652.
    陈求凝, 张雪梅, 谢邦贵, 等. 不同抗菌药物对肺部感染新生儿肠道菌群及消化系统影响的研究[J]. 中华医院感染学杂志, 2018, 28(16): 2531-2534.
    • Related Articles

  • Related Articles

    [1]MENG Xiangzhong, WEI Feng, WANG Na, SHI Zhenhua, DING Dongrui. Clinical analysis of plasma procalcitonin and C-reactive protein levels in 65 patients with septic shock[J]. Journal of Clinical Medicine in Practice, 2018, (3): 120-122. DOI: 10.7619/jcmp.201803035
    [2]REN Wenjun, LIU Xiaolan. Value of serum procalcitonin in prognosis diagnosis of patients with sepsis[J]. Journal of Clinical Medicine in Practice, 2016, (21): 48-51. DOI: 10.7619/jcmp.201621015
    [3]LI Zhi. Changes and diagnostic value of serum procalcitonin and C-reactive protein in patients with severe infection in ICU[J]. Journal of Clinical Medicine in Practice, 2016, (5): 70-72. DOI: 10.7619/jcmp.201605021
    [4]ZHNG Geng, DENG Bingqu, ZHAN Daliang. Predictive value of serum procalcitonin in diagnosis and prognosis for aged patients with community-acquired pneumonia[J]. Journal of Clinical Medicine in Practice, 2015, (23): 37-40. DOI: 10.7619/jcmp.201523012
    [5]LIU Chijia, CUI Yuntao, ZHANG Aimin. Change and significance of serum procalcitonin and C-reactive protein levels in cerebral hemorrhage patients complicated with infection[J]. Journal of Clinical Medicine in Practice, 2015, (13): 27-29. DOI: 10.7619/jcmp.201513008
    [6]XU Bin, FAN Zhigang, YANG Yun, XU Zongxian. Application of serum procalcitonin and C-reactive protein detections in the diagnosis of neonatal severe infectious disease[J]. Journal of Clinical Medicine in Practice, 2014, (24): 50-52. DOI: 10.7619/jcmp.201424015
    [7]LI Yuanhua, SONG Xiuchan, QI Yingjing, ZENG Peiyang, WU Suhua, LAI Zhijun, XIE Shufeng. Value of plasma procalcitonin level detection in treatment of pyemia[J]. Journal of Clinical Medicine in Practice, 2014, (15): 155-157. DOI: 10.7619/jcmp.201415054
    [8]CHEN Jun, XHAO Lan, BI Jing. Clinical significance of serum procalcitonin and IL-6 detection in diagnosis and treatment of patients with chronic obstructive pulmonary disease[J]. Journal of Clinical Medicine in Practice, 2014, (9): 144-145. DOI: 10.7619/jcmp.201409050
    [9]TANG Haicheng, BO Hongjian, ZHOU Zhixiang, ZHANG Qun, JIANG Yongqian, MA Da. Clinical significance of serum procalcitonin detection in antibiotic treatment of patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Journal of Clinical Medicine in Practice, 2013, (24): 16-19,23. DOI: 10.7619/jcmp.201324005
    [10]YU Lan, ZHANG Jifang, LI Yunfang. Application of cefoperazone/sulbactam sodium in the prevention and treatment of obstetric and gynecological infections[J]. Journal of Clinical Medicine in Practice, 2013, (14): 68-70. DOI: 10.7619/jcmp.201314023

  • Cited by

    Periodical cited type(30)

    1. 韩美玲，严颖，许甜甜，王佳，陆玉梅. 风险等级防控护理对重症肺炎俯卧位通气治疗患者安全性与疗效的影响. 中国急救复苏与灾害医学杂志. 2024(04): 526-529 .
    2. 龙婷. 苏黄止咳胶囊辅助头孢哌酮舒巴坦治疗老年肺部感染患者的临床效果观察. 现代诊断与治疗. 2024(03): 332-334+337 .
    3. 王怡，周燕萍. 哌拉西林他唑巴坦钠与头孢哌酮舒巴坦钠治疗老年重症肺炎的疗效研究. 川北医学院学报. 2024(06): 843-846 .
    4. 李欣，龚廷信. 哌拉西林钠他唑巴坦钠与头孢哌酮钠舒巴坦钠在重症肺炎患者中的应用效果对比. 实用中西医结合临床. 2024(07): 82-85 .
    5. 周元武. 注射用亚胺培南西司他丁钠对重症肺炎疗效及病程的影响分析. 基层医学论坛. 2024(19): 64-66 .
    6. 左远航，焦相赟，李想，冯丽霞. 多索茶碱联合头孢哌酮舒巴坦钠治疗重症肺炎的效果. 中国药物滥用防治杂志. 2024(08): 1465-1468 .
    7. 吴水英，廖舆珍. 老年重症肺炎干预中头孢哌酮钠舒巴坦钠结合莫西沙星的作用. 北方药学. 2024(10): 187-189 .
    8. 吕芳. 莫西沙星联合哌拉西林钠他唑巴坦钠对老年重症肺炎患者症状消失、炎症指标的影响. 天津药学. 2024(06): 61-64 .
    9. 邓婉君. 枯草杆菌二联活菌颗粒联合头孢哌酮钠舒巴坦钠治疗重症肺炎患儿的临床效果. 临床合理用药. 2023(05): 127-129+133 .
    10. 刘晶晶，王传宝，刘媛. 替加环素联合头孢哌酮/舒巴坦治疗泛耐药鲍曼不动杆菌老年重症肺炎的临床观察. 贵州医药. 2023(02): 247-248 .
    11. 许丹，吴长江. 头孢哌酮钠舒巴坦钠联合替加环素治疗多重耐药菌重症肺炎的效果分析. 系统医学. 2023(01): 94-97 .
    12. 吴萍，彭怡琳，聂辰. 莫西沙星联合头孢哌酮舒巴坦钠治疗老年重症肺炎的有效性及安全性研究. 中外医疗. 2023(12): 139-142 .
    13. 高桂芹，李之红. 美洛西林钠舒巴坦钠治疗新生儿肺炎的疗效分析. 中国实用医药. 2023(13): 12-15 .
    14. 江宗虎. 莫西沙星联合头孢哌酮舒巴坦钠治疗老年重症肺炎的疗效观察. 北方药学. 2023(05): 18-19+22 .
    15. 刘晨露，程庆荣，檀崇斌，汪丽，杨东梅，朱倩. 新冠病毒合并呼吸道细菌感染临床特点及抗感染药物评价. 热带医学杂志. 2023(09): 1294-1298 .
    16. 张一虹，汪群芳. 体外膈肌起搏器联合头孢哌酮钠舒巴坦钠治疗老年痴呆合并肺部感染疗效及对炎性因子和血气分析的影响. 中国老年学杂志. 2023(21): 5199-5202 .
    17. 张玉红，宋凤莲，陈勇. 胸腺法新在慢性阻塞性肺疾病合并肺部感染中的效果及对免疫功能的影响. 转化医学杂志. 2023(05): 241-244 .
    18. 何青萍. 头孢哌酮钠舒巴坦钠对革兰阴性社区获得性肺炎患者炎性应激指标的影响. 现代诊断与治疗. 2023(22): 3385-3387+3427 .
    19. 钟睿. 头孢他啶与注射用头孢哌酮钠舒巴坦钠在肝损害伴肺部感染患者中的应用对比及药物经济学评价分析. 中国处方药. 2022(01): 132-134 .
    20. 陈艳艳. 肺部感染评分在老年重症肺炎患者抗菌药物选择中的应用效果. 中国民康医学. 2022(05): 147-149 .
    21. 杜凤川，宋培培，张京乐. 头孢哌酮舒巴坦与清金化痰汤治疗对肺炎中医症候积分、血清学指标、肺功能的影响. 临床研究. 2022(02): 103-106 .
    22. 龙幼斯. ICU重症感染患者的抗感染治疗中不同抗菌药物的治疗效果及对患者病原菌清除效果. 智慧健康. 2022(04): 100-102 .
    23. 贾金，张明霞，李莹，张晓月，黄迎春. 两种不同抗菌药物治疗非重症老年医院获得性肺炎的临床研究. 世界临床药物. 2022(05): 576-581 .
    24. 曲思澄. 莫西沙星联用头孢哌酮钠舒巴坦钠治疗老年重症肺炎的临床效果分析. 中国实用医药. 2022(16): 136-138 .
    25. 杜江涛，李扬，欧阳山丹，刘炳震，林珍. 替加环素联合头孢哌酮舒巴坦治疗ICU重度腹腔感染的效果. 国际医药卫生导报. 2022(21): 3077-3081 .
    26. 宋明君. 西药药剂头孢哌酮钠舒巴坦钠的临床应用效果研究. 中国实用医药. 2021(08): 118-120 .
    27. 叶伟强，曾庆栈. 重症细菌性肺炎患者病原菌分布与抗菌类药物使用相关性分析. 黑龙江医药. 2021(03): 592-595 .
    28. 崔丽. 高剂量替加环素联合注射用头孢哌酮钠舒巴坦钠治疗肺部多重耐药菌感染患者的效果. 河南医学研究. 2021(16): 2980-2982 .
    29. 许静刚. 支气管镜灌洗术联合特布他林治疗老年重症肺部感染合并慢性阻塞性肺疾病的临床价值. 现代实用医学. 2021(10): 1381-1383 .
    30. 郭镕杰，蔡玲玲，杨淑贞. 胸腺法新联合头孢哌酮舒巴坦钠对重症肺炎患者炎性因子水平及免疫功能的影响. 医学理论与实践. 2021(24): 4272-4274 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (404) PDF downloads (15) Cited by(30)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return